Navigation Links
NexBio(R) Demonstrates DAS181 (Fludase(R)*), a Broad-Spectrum Drug Candidate, Inhibits Influenza Viral Infection in Human Lung Tissue
Date:8/25/2009

g and commercializing novel, broad-spectrum biopharmaceuticals to prevent and treat current and emerging life-threatening diseases. DAS181 (Fludase((R))), a recombinant fusion protein, inactivates viral receptors on the cells of the human respiratory tract, thereby preventing and treating infection by influenza, including potential pandemic strains, and by parainfluenza viruses (which may cause serious respiratory illness similar to influenza and for which there is no approved vaccine or therapeutic). Unlike current antiviral compounds and vaccines, DAS181 targets human host receptors, not virus components, and thus carries a reduced risk of drug resistance compared with currently-available antiviral drugs. Extensive, prolonged nonclinical studies have not shown the development of any meaningful resistance. Viradin((TM)), invented and developed by NexBio, is a parenteral protein under development, currently at lead optimization stage, directed to the treatment of viral hemorrhagic fevers and bacterial biothreat sepsis. TOSAP((TM)) is a technology invented and developed by NexBio and is used to formulate DAS181 for inhalation, as well as to make nano/microparticles from virtually any type of molecule. TOSAP((TM)) is offered for the formulation of compounds of partners, under license.

For more information about NexBio, Inc., please visit http://www.nexbio.com

    Contact:

    David Wurtman, M.D., M.B.A
    VP, Corporate Development
    10665 Sorrento Valley Road
    San Diego, CA  92121
    Phone: (858) 452-2631
    dwurtman@nexbio.com

* FDA has yet to approve the name Fludase.

DISCLOSURE NOTICE:

This release contains forward-looking information about the research and development program of
'/>"/>

SOURCE NexBio, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Data Published in Cell Stem Cell Demonstrates Potent Anti-Cancer Activity for OncoMed Pharmaceuticals Lead Antibody
2. Abbott HIV Test Demonstrates Earlier Disease Detection
3. BioNeutrals Ygiene(TM) Hospital Grade Antimicrobial Demonstrates a 99.9997% Kill Rate Against Clostridium Difficile Spores (C.diff) in Independent Lab Pre-testing Phase
4. New Pre-Clinical Data on OmniGuides BeamPath NEURO(TM) Demonstrates Precise Cutting in Brain Tissue
5. Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia
6. PROSTVAC(TM) Data Presented at the ASCO Meeting Demonstrates the Potential for Significant Increases in Life Expectancy in Late-Stage Prostate Cancer
7. NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS
8. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
9. SemBioSys plant-derived Apo AI(Milano) demonstrates encouraging biologic activity in seven preclinical models
10. OrbusNeichs Genous(TM) Bio-engineered R stent(TM) Demonstrates Impressive Results in Higher Risk Patients
11. Finesse Demonstrates TruFluor(TM) pH, a Single-Use Optical pH Sensor and Transmitter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... UAE (PRWEB) October 22, 2014 Grace ... science and healthcare projects, announces the addition of ... DCH to its advisory team. Dr. Siddiqui will provide ... , A graduate of University College Medical ... subsequently degreed in medicine in 2001. With further certification ...
(Date:10/22/2014)... , Oct. 22, 2014 /PRNewswire/ - iCo Therapeutics ... today announced next steps for its Oral Amphotericin ... from its in vitro work involving ... iCo now plans to complete pre clinical studies ... initial Phase 1A clinical trial, utilizing approximately $700,000 ...
(Date:10/20/2014)... The report “Pharmacy Automation Systems Market by ... Systems, Table-top Counters) by End-user (Inpatient Pharmacy Automation, ... to 2019” analyzes and studies the major market ... Asia-Pacific, and the Rest of the World (RoW). ... spread through 300 pages and in-depth TOC on ...
(Date:10/20/2014)... Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced four new ... and provides a good start to Q4.  The orders are for ... and one in the Middle East . ... Peter Bruijns , President & CEO. "Total bidding activity and ... have been for any complete year since the company has tracked ...
Breaking Biology Technology:Dr. Yousef Siddiqui joins the Grace Century Advisory Team 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4
... and a better understanding of climate change are in ... University Belfast,s Institute of Electronics, Communications and Information Technology ... high performance electronic device - known as a dual ... be used in future European Space Agency (ESA) missions. ...
... Recent advances in modern manufacturing techniques,has made it ... high accuracies.,In direct response to the extreme demands ... and,position of microsystem parts, extensive research,is being carried ... micro-scale. , ,Microparts, is a joint EURAMET research ...
... ST. LOUIS, Aug. 7 KV Pharmaceutical Company (NYSE: KVa/KVb) (the ... Company,s Class A and Class B Common Stock, as further described ... purported to have been taken by such Reporting Persons on August ... By-Laws and is therefore invalid and not effective. , , ...
Cached Biology Technology:Research breakthrough will lead to more accurate weather forecasts 2KV Pharmaceutical Announces Stockholder Action to Amend By-Laws is Invalid 2KV Pharmaceutical Announces Stockholder Action to Amend By-Laws is Invalid 3KV Pharmaceutical Announces Stockholder Action to Amend By-Laws is Invalid 4KV Pharmaceutical Announces Stockholder Action to Amend By-Laws is Invalid 5KV Pharmaceutical Announces Stockholder Action to Amend By-Laws is Invalid 6
(Date:10/16/2014)... Conn. , October 16, 2014 NXT-ID, ... or the "Company"), a biometric authentication company focused on ... its leading edge technologies including Wocket™, the Smart Wallet, ... (FiRe) Conferenece. FiRe is a leading global conference on ... Hosted by Mark Anderson , founder and ...
(Date:10/15/2014)... is spreading rapidly and to an unexpected extent. The ... past and the virus shows a new disease dynamic ... For this reason, the German National Academy of Sciences ... Engineering, and the Union of the German Academies of ... Ebola epidemic today. , In the statement the academies ...
(Date:10/14/2014)... – Like discriminating thieves, prostate cancer tumors scavenge and ... body. But such avarice may be a fatal weakness. ... way to kill prostate cancer cells by delivering a ... destroys the diseased cells brimming with the mineral, leaving ... two drugs already commercially available for other uses, could ...
Breaking Biology News(10 mins):NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3Academies call for consequences from the Ebola virus epidemic 2Academies call for consequences from the Ebola virus epidemic 3Academies call for consequences from the Ebola virus epidemic 4Academies call for consequences from the Ebola virus epidemic 5Prostate cancer's penchant for copper may be a fatal flaw 2
... Monkeys living on an island without big cat predators do ... played to them, according to research by a UC Davis ... hurry from the sound of human voices. "This contributes ... relaxed selection pressures," said Jessica Yorzinski, a graduate student in ...
... much more significant role in a persons ability to ... than previously understood, say scientists. Writing in Nature ... nutrients in the environment are critical to the fitness ... The findings for the first time provide a ...
... NEW YORK (Jan. 16, 2008) -- Two major federal grants ... Medical College in New York City. Dr. Kenneth ... NIH grant from the National Institute on Drug Abuse (NIDA) ... prevention program previously delivered to urban minority youth attending New ...
Cached Biology News:Diet and lifestyle critical to recovery, says study 22 federal public health grants awarded to Weill Cornell Medical College 2
... highest precision, more user-friendliness and absolute reliability ... the definition of the Mastercycler ep system. ... research has been developing dynamically. The same ... Systems. To keep pace with these ...
... is designed for easy transformation of the ... for successful transformation simply by mixing a ... cultured yeast cells. No complicated steps, such ... The kit is particularly well suited for ...
... easier. It offers a wide array of features for ... *Instruments supported: Control ... PR, SR, PG-S, PG, SG, AT, MT, UMT, AB-S, ... User guidance on the balance display ...
... powder ,Components g/500 ml: ... ,Sodium chloride 2.5 ,Agar 6.0 ... 0.250 ,IPTG 0.025 ,Kanamycin 0.0175 ... a complete growth medium containing ...
Biology Products: